Market Research Report
Global Human Microbiome Therapeutics Market - 2019-2026
|Published by||DataM Intelligence||Product code||803301|
Delivery time: 1-2 business days
|Global Human Microbiome Therapeutics Market - 2019-2026|
|Published: December 1, 2019||Content info:||
Global Human Microbiome Therapeutics Market Overview
The global human microbiome therapeutics market is expected to grow at a CAGR of XX% to reach a market value of USD XX million by 2026.
The microbiome therapeutics are currently being assessed for many indications, so the target patient pool is the sum of number of patients pertaining to such indications. Further, the drugs are also evaluated for indications with high patient pool such as diabetes and lactose intolerance. So, the global patient pool for microbiome therapeutics is substantially huge.
The microbiome therapeutics are expected to launch in the mid 2020 for gastrointestinal disorders and dermatological conditions. SER-109 (Seres Therapeutics) and RBX2660 (Ferring pharmaceuticals) are being evaluated for recurrent clostridium difficile infection (CDI) infections. Clostridium difficile is a major nosocomial pathogen recognized globally as an enteric pathogen responsible for clostridium difficile infection (CDI), antibiotic-associated diarrhoea (AAD) and colitis. According to the reports, the incidence of C. difficile infection (CDI) has dramatically increased globally due to frequent usage of broad-spectrum antibiotics in these patients. Further, it has been reported that the prevalence of CDIs is around 20%-30% and in India as 15%-20% in patients taking antibiotics. The infection has high chances of recurrence close to 25% of the cases. After the first recurrence, the chances increase to 65%. So, it has been estimated that the burden of recurrent CDI is around 85,000 to 110,000 in the U.S. only.
Global Human Microbiome Therapeutics Market - Market Dynamics
The global market for ablation catheters is primarily driven by the rise in prevalence of Metabolic Diseases, Dermatological Conditions and Other Disorders (Cardiovascular, CNS, Cancer) with the rise in the elderly population.
Metabolic disorders are inherited from ancestors or acquired during the lifetime. These disorder create issues with the normal metabolism of human body are severely impacts the patient lifestyle. For instance, Phenylketonuria is an example of inherited metabolic disorder, in which the body is unable to breakdown the amino acid phenylalanine. Other prominent metabolic disorders include lactose intolerance, cystinosis, type 1 diabetes, maple syrup urine disease, Gaucher's disease, Fabry disease, Hartnup disease, Hunter syndrome, and Hurler syndrome
Dermatology condition is majorly driven by rising prevalence of skin cancer and other skin diseases. Further, growing aesthetic appeal in young population positively impacts the market growth of this sector.
AOBiome, LLC, MatriSys Biosystem, AOBiome, and Intrexon are some of the players which invested in microbiome therapeutics for dermatological conditions. AOBiome is considered as a key player in this sector as its drug is in trials for several conditions such as Acne Vulgaris; Atopic Dermatitis Eczema; Allergic Rhinitis; and Chronic Wounds.
Global Human Microbiome Therapeutics Market - Segment Analysis
By disease indication, the human microbiome therapeutics market is segmented into gastrointestinal disorders, metabolic disorder, women health, cancer, and others. The gastrointestinal disorders share the most established market due to its Increasing incidences of gastrointestinal disorders followed by infectious diseases.
Increasing incidences of gastrointestinal disorders that demands treatment is expected to boost this sector of microbiome therapeutics market. In addition, unhealthy dietary habits, increasing stress and rising geriatric population drives the growth of sector. Although gastrointestinal disorders are significantly impacts economic burden, but many digestive diseases are still poorly understood and treatment options are far from optimal, leaving many patients dissatisfied with their current treatment. For instance, recurrence of Clostridium Difficile Infection (CDI) is around 25% and chances of further recurrence rises up to 65%. Microbiome therapeutics checks the recurrence and thus, possess huge opportunity in this sector.
Global Human Microbiome Therapeutics Market - Geographical Analysis
North America market accounted for the largest share in the human microbiome therapeutics market. It is attributed to the increasing pipeline products to treat gastrointestinal disorders, dermatological indication, etc.
The first launch of human microbiome therapeutics in the United States, could for the gastrointestinal disorders (Clostridium Difficile Infection (CDI) specifically for the recurrent CDI) and for the dermatological indication (for acne vulgaris). The expected launch of the RBX2660 (Ferring pharmaceuticals) in the year 2020 for the recurrent CDI shall fill the void of highly unmet need. RBX-2660 is a therapy under development for recurrent CDI. It is a non-antibiotic therapy that consists of human-derived microorganisms (microbiota suspension). It is administered directly into the patient's intestine through the rectum as an enema. RBX-2660 has the potential to treat patients reinfected by C. difficile that currently have limited treatment options available and are at risk of serious health consequences.
Another drug for the same indication is SER-109 of Seres Therapeutics. Seres appears to be the leading pharmaceutical firm in the field of microbiome therapies. Seres estimates 85,000 to 110,000 recurrent CDI patients in the U.S. (with a midpoint of 97,500); presumably, the range is the number of new patients each year. It is expected to hit the market in 2021 after launch of RBX-2660 in 2020, thus contribute to increase the market size of gastrointestinal disorder (recurrent CDI).
Global Human Microbiome Therapeutics Market- Competitive Analysis
Key players are adopting strategies such as product launches, mergers and acquisitions, partnerships, and regional expansion to stand out as strong competitors in the market. New product launches along with increased focus on R&D are other ways the leading players improve their market presence.
In June 2018, 4D Pharma had an agreement with a subsidiary of MSD (trade name of Merck & Co., Inc., Kenilworth, N.J., USA) to conduct a clinical trial evaluating the combination of Keytruda (pembrolizumab), an anti-PD-1 therapy marketed by MSD, and 4D pharma's live biotherapeutic candidate MRx0518 in patients with solid tumours.
In April 2018, Synthetic Biologics entered into a preliminary agreement from the U.S. Food & Drug Administration (FDA), on a proposed clinical trial synopsis for its planned Phase III clinical trial for SYN-004 (ribaxamase).
In January 2018, Rebiotix announced its successful first phase of collaboration with CoreBiome to measure the ability of RBX2660 and RBX7455 to rehabilitate the human microbiome impacted by recurrent Clostridium difficile (C. diff) infection.
In January 2017, Ritter Pharmaceuticals entered into collaboration with University of Nebraska for studying the role of microbiome and RP-G28 in metabolic syndrome